Navigation Links
His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
Date:2/14/2008

NEW YORK, Feb. 14 /PRNewswire/ -- His Royal Highness, The Duke of York, was the guest of honour today at a lunch held to mark the United States launch of UK-based specialty pharmaceutical company, ProStrakan Group plc (LSE: PSK). ProStrakan's first US product, Sancuso, is currently under consideration for licensing by the US Food & Drug Administration.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 )

Prince Andrew is visiting the United States as the UK's Special Representative for International Trade & Investment. He accepted the invitation to today's lunch after visiting ProStrakan's headquarters in Galashiels, Scotland, last year at which time he was briefed on ProStrakan's plans for expansion into the US.

Commenting on today's visit, The Duke of York said:

"It gives me great pleasure to see ProStrakan establish itself in the United States. I was hugely impressed by the company's ambition and drive when I visited their headquarters in Galashiels last year. I am committed to doing everything I can to help UK companies like ProStrakan expand still further into the global marketplace."

ProStrakan's Chief Executive Officer, Dr Wilson Totten, the host of the lunch, said:

"ProStrakan was founded on a commitment to developing innovative products to meet the needs of patients. With that, we are pleased to announce our US business and today's event has marked our arrival here in the best possible way.

"We were delighted when Prince Andrew visited us in Galashiels last year but to have him join us as guest of honour today here in New York was a special privilege."

Also attending today's lunch were guests representing ProStrakan's US business partners, including Ron Wooten, Executive Vice President of Quintiles Transnational and President of NovaQuest; Patrick Jordan, Vice President of NovaQuest; and advisors and staff in the US. The lunch was held at Manhattan's Carlyle Hotel.

ProStrakan has established its US headquarters in Bedminster, New Jersey. The company has partnered with NovaQuest to recruit a 75-person sales force to commercialize ProStrakan's products in the US. NovaQuest is the strategic partnering group of Quintiles Transnational, the world's leading pharmaceutical services company. Once recruited, it is planned that the sales force will promote ProStrakan's Sancuso.

Sancuso is a transdermal patch that delivers granisetron, an established 5-HT3 receptor antagonist, steadily into the bloodstream over a number of days, helping to prevent the side-effects of nausea and vomiting in patients undergoing chemotherapy without the need for injection or having to swallow pills.

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries. http://www.prostrakan.com

NovaQuest

NovaQuest, the strategic partnering group of Quintiles Transnational, is an industry pioneer in offering tailored financial and operational solutions that help pharmaceutical and biotech companies overcome development and commercialization challenges. Its unique managed partnership approach ensures sponsorship by senior-level executives; access to global development and commercial resources and expertise; and efficient operational delivery of services. Since 2000, NovaQuest partnerships have committed more than $2 billion in capital to pharmaceutical and biotech companies of all sizes. For more information, please visit http://www.novaquest.com.


'/>"/>
SOURCE ProStrakan Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share
2. Royalty Pharma Acquires a Portion of Northwestern Universitys Royalty Interest in Lyrica(R) for $700 Million
3. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
4. British Royal highlights anesthesia crisis in the developing world
5. Virtual Hold Technology Donates Toys, Helps Raise Money for WKDDs Annual Radiothon for Akron Childrens Hospital
6. Oracle Helps Mayo Clinic Improve Information Management
7. Sucking Out Clot Debris Helps Heart Attack Patients
8. Wild Animal Crunch(TM) Helps Moms Tame Families Hunger
9. Drug Helps Prevent Breast-Feeding Moms From Passing on HIV
10. VMware Desktop Virtualization Helps Healthcare Providers Improve Patient Care
11. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has officially broken ... Children’s Hospital. Over 3,000 people looked on as the shovels hit the dirt at ... slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, ... the official relaunch of its community and education hub for women considering fertility ... is to create a safe and welcoming place for women to find cycle ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence in Wellness, powered ... Young Living Essential Oils, taught by Patti Dolan, RYT, a Young Living Gold ... Flow is 6:30pm - 7:15pm followed by a small intro to the Oils that ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in Houston, ... contaminated well water throughout the Houston area. , Heavy floodwaters have led to destroyed ... to contaminants. Residents may not even be aware of the contamination of their water ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
(Date:5/23/2016)... May 23, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 ... Other), by Application (Drug Discovery and Development, Proteomics, ... (Pharmaceuticals, Life Science and Biotechnology, Academic and Research ... Research, the global mass spectrometry market ...
(Date:5/23/2016)... , May 23, 2016 ... for detection of multiple diseases; ,Technology to be presented ... Yissum Research Development Company of the Hebrew ... into a research agreement with Aurum Ventures MKI, the technology ... development of a new diagnostic approach for early detection ...
Breaking Medicine Technology: